医学检验与临床
醫學檢驗與臨床
의학검험여림상
MEDICAL LATORATORY SCIENCE AND CLINICES
2013年
3期
39-40,32
,共3页
鲍曼不动杆菌%多重耐药性%抗生素
鮑曼不動桿菌%多重耐藥性%抗生素
포만불동간균%다중내약성%항생소
Acinetobacter baumannii%Multidrug resistance%Antibiotics
目的:通过对微生物室分离的鲍曼不动杆菌检测结果进行分析,了解本院鲍曼不动杆菌的临床分布和耐药情况,以加强临床医师对鲍曼不动杆菌感染的预防和控制。方法:收集2012年1月-2012年12月检验科微生物室分离的244株鲍曼不动杆菌,进行药敏检测,分析其临床分布特点和药敏情况。结果:244株鲍曼不动杆菌主要来源于ICU病房(32.18%),脑外科(19.54%),烧伤科(12.64%),呼吸内科(10.35%);标本以痰液为主(78.16%),其次为脓液(17.24%);药敏结果显示本院分离的鲍曼不动杆菌对氨苄西林、头孢唑啉、头孢西丁等耐药率为100%,其次为头孢呋新钠和头孢呋新酯(96.30%),头孢匹美(86.59%),左氧氟沙星(78.16%),头孢噻肟(77.91%),丁胺卡那霉素(77.11%),头孢他啶(77.01%),哌拉西林/他唑巴坦(70.73%),美罗培南(63.41%),亚胺培南(62.07%),头孢哌酮/舒巴坦(32.14%),耐药率最低的药物为米诺环素(28.00%)。大部分为多重耐药菌株(70.12%)。结论:本院鲍曼不动杆菌耐药现象非常严重,各临床科室应注重抗生素的合理使用,加强预防和控制鲍曼不动杆菌感染。
目的:通過對微生物室分離的鮑曼不動桿菌檢測結果進行分析,瞭解本院鮑曼不動桿菌的臨床分佈和耐藥情況,以加彊臨床醫師對鮑曼不動桿菌感染的預防和控製。方法:收集2012年1月-2012年12月檢驗科微生物室分離的244株鮑曼不動桿菌,進行藥敏檢測,分析其臨床分佈特點和藥敏情況。結果:244株鮑曼不動桿菌主要來源于ICU病房(32.18%),腦外科(19.54%),燒傷科(12.64%),呼吸內科(10.35%);標本以痰液為主(78.16%),其次為膿液(17.24%);藥敏結果顯示本院分離的鮑曼不動桿菌對氨芐西林、頭孢唑啉、頭孢西丁等耐藥率為100%,其次為頭孢呋新鈉和頭孢呋新酯(96.30%),頭孢匹美(86.59%),左氧氟沙星(78.16%),頭孢噻肟(77.91%),丁胺卡那黴素(77.11%),頭孢他啶(77.01%),哌拉西林/他唑巴坦(70.73%),美囉培南(63.41%),亞胺培南(62.07%),頭孢哌酮/舒巴坦(32.14%),耐藥率最低的藥物為米諾環素(28.00%)。大部分為多重耐藥菌株(70.12%)。結論:本院鮑曼不動桿菌耐藥現象非常嚴重,各臨床科室應註重抗生素的閤理使用,加彊預防和控製鮑曼不動桿菌感染。
목적:통과대미생물실분리적포만불동간균검측결과진행분석,료해본원포만불동간균적림상분포화내약정황,이가강림상의사대포만불동간균감염적예방화공제。방법:수집2012년1월-2012년12월검험과미생물실분리적244주포만불동간균,진행약민검측,분석기림상분포특점화약민정황。결과:244주포만불동간균주요래원우ICU병방(32.18%),뇌외과(19.54%),소상과(12.64%),호흡내과(10.35%);표본이담액위주(78.16%),기차위농액(17.24%);약민결과현시본원분리적포만불동간균대안변서림、두포서람、두포서정등내약솔위100%,기차위두포부신납화두포부신지(96.30%),두포필미(86.59%),좌양불사성(78.16%),두포새우(77.91%),정알잡나매소(77.11%),두포타정(77.01%),고랍서림/타서파탄(70.73%),미라배남(63.41%),아알배남(62.07%),두포고동/서파탄(32.14%),내약솔최저적약물위미낙배소(28.00%)。대부분위다중내약균주(70.12%)。결론:본원포만불동간균내약현상비상엄중,각림상과실응주중항생소적합리사용,가강예방화공제포만불동간균감염。
Objective:To enhance the prevention and control of Acinebacter baumannii infection of clinicians through analyzing the distribution and resistance characteristic of clinical Acinetobacter baumannii. Methods:244 strains of Acinetobacter baumannii were collected from January to December in 2012,drug susceptibility test was carried. The distribution of clinical characteristics and drug sensitivity were analyzed.Results:244 Acinetobacter baumannii mainly isolated from the ICU (32.18%), neurosurgery (19.54%), burns (12.64%), respiratory medicine (10.35%); sputum was the main source of specimens(78.16%), followed by of pus (17.24%); susceptibility results show the resistance rates to ampicillin, cefazolin, cefoxitin resistance rate of 100%, followed by cefuroxime sodium and cefuroxime ester (96.30%), cefpiramide America (86.59%), levofloxacin (78.16%), cefotaxime (77.91%), amikacin (77.11%), ceftazidime (77.01%), piperacillin/tazobactam (70.73%), meropenem (63.41%), imipenem (62.07%), cefoperazone/ sulbactam (32.14%), the lowest rate of drug resistance to minocycline (28.00% ). Most of the Acinetobacter baumannis are multi-resistant strains (70.12%).Conclusions:Resistant condition of Acinetobacter baumannii in this hospital is very serious, clinical departments should focus on the rational use of antibiotics, strengthen the prevention and control of Acinetobacter baumannii infections.